{"id":"https://openalex.org/W3083661547","doi":"https://doi.org/10.1158/1538-7445.am2020-564","title":"Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models","display_name":"Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083661547","doi":"https://doi.org/10.1158/1538-7445.am2020-564","mag":"3083661547"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-564","doi":"https://doi.org/10.1158/1538-7445.am2020-564","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-564","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029873173","display_name":"Hiroshi Sootome","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120269","display_name":"Taiho Pharmaceutical (Japan)","ror":"https://ror.org/02v50dx14","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210120269"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroshi Sootome","raw_affiliation_strings":["1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;","institution_ids":["https://openalex.org/I4210120269"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034292501","display_name":"Akihiro Miura","orcid":"https://orcid.org/0000-0002-1217-7220","observed_orcids":["https://orcid.org/0000-0002-1217-7220"]},"institutions":[{"id":"https://openalex.org/I4210120269","display_name":"Taiho Pharmaceutical (Japan)","ror":"https://ror.org/02v50dx14","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210120269"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akihiro Miura","raw_affiliation_strings":["1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;","institution_ids":["https://openalex.org/I4210120269"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030733486","display_name":"Toshiharu Komori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120269","display_name":"Taiho Pharmaceutical (Japan)","ror":"https://ror.org/02v50dx14","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210120269"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshiharu Komori","raw_affiliation_strings":["2Taiho Pharmaceutical Co., Ltd., Tokushima, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Taiho Pharmaceutical Co., Ltd., Tokushima, Japan","institution_ids":["https://openalex.org/I4210120269"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090989020","display_name":"Hiroshi Hirai","orcid":"https://orcid.org/0000-0002-4784-5110","observed_orcids":["https://orcid.org/0000-0002-4784-5110"]},"institutions":[{"id":"https://openalex.org/I4210120269","display_name":"Taiho Pharmaceutical (Japan)","ror":"https://ror.org/02v50dx14","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210120269"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroshi Hirai","raw_affiliation_strings":["1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan;","institution_ids":["https://openalex.org/I4210120269"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210120269"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"564","last_page":"564"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/futibatinib","display_name":"futibatinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.8169999718666077},{"id":"https://openalex.org/keywords/fgfr2-amplification","display_name":"FGFR2 amplification","score":0.8130000233650208},{"id":"https://openalex.org/keywords/fgfr2-mutations","display_name":"FGFR2 mutations","score":0.7730000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5929999947547913},{"id":"https://openalex.org/keywords/chemotherapy-synergy","display_name":"chemotherapy synergy","score":0.7910000085830688},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.8399999737739563},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9789999723434448},{"id":"https://openalex.org/keywords/s-1","display_name":"S-1","score":0.843999981880188},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9760000109672546},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9729999899864197},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9580000042915344},{"id":"https://openalex.org/keywords/parp-cleavage","display_name":"PARP cleavage","score":0.8820000290870667},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.8276437520980835},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.7858895659446716},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6960870623588562},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5427356958389282},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5190156698226929},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4781675934791565},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4391605257987976},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38420185446739197},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.31866031885147095},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2399977445602417},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08165088295936584}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-564","doi":"https://doi.org/10.1158/1538-7445.am2020-564","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-564","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3083235786","https://openalex.org/W3089208853","https://openalex.org/W4382799190","https://openalex.org/W4220781136","https://openalex.org/W4388653430","https://openalex.org/W4388792564","https://openalex.org/W4382645613","https://openalex.org/W4323826889","https://openalex.org/W3200616010","https://openalex.org/W3198909341"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Futibatinib,":[2],"a":[3,208,224,279,317],"selective,":[4],"irreversible":[5],"fibroblast":[6],"growth":[7,92,149,179,194],"factor":[8],"receptor":[9],"(FGFR)":[10],"1-4":[11],"inhibitor,":[12],"has":[13],"antitumor":[14,23,109,281],"activity":[15],"in":[16,39,40,43,74,125,157,182,197,212,235,283,286],"FGFR-deregulated":[17,199,322],"cancer":[18,53,200,323],"models.":[19,45],"The":[20,108],"potential":[21],"synergistic":[22,145,280,318],"effects":[24,110],"of":[25,79,111,332,336],"targeted":[26],"therapy":[27],"plus":[28,113,119,155,188,217,230,314],"chemotherapy":[29,315],"(chemo)":[30],"was":[31,81,93,151],"evaluated":[32,124],"by":[33,83,95,137],"combining":[34],"futibatinib":[35,63,80,112,118,154,187,216,229,241],"with":[36,56,62,153,186,215,228,240,290],"cytotoxic":[37,65,292],"agents":[38,66],"vitro":[41,77,284],"and":[42,51,64,117,129,170,176,223,285,298,326,347],"vivo":[44,287],"Methods:":[46],"Gastric,":[47],"breast,":[48],"lung,":[49],"endometrial,":[50],"bladder":[52],"cell":[54,91,148,178,193,201,324],"lines":[55,325],"various":[57,198,291,321],"FGFR":[58],"aberrations":[59],"were":[60,123,163,180],"treated":[61,185,239],"(5-FU,":[67],"paclitaxel,":[68],"cisplatin,":[69],"or":[70,73,105,115,121,221,242,244],"gemcitabine)":[71],"individually":[72],"combination.":[75],"In":[76,203],"cytotoxicity":[78],"assessed":[82],"PARP":[84,174],"cleavage":[85,175],"activity.":[86],"Any":[87],"combination":[88,100,245],"effect":[89,146,282,319],"on":[90,147],"determined":[94],"the":[96,333,337],"Bliss":[97],"independence":[98],"method,":[99],"index":[101],"(CI;":[102],"CalcuSyn":[103],"software),":[104],"isobologram":[106],"analysis.":[107],"S-1":[114],"paclitaxel":[116,219,243,259,264],"gemcitabine":[120],"cisplatin":[122,222],"gastric":[126],"FGFR2-amplified":[127],"SNU-16":[128,158,183,236],"endometrial":[130],"FGFR2-N549K-mutated":[131],"AN3CA":[132],"mouse":[133,237],"xenograft":[134,204,327],"models,":[135,205],"respectively,":[136],"measuring":[138],"relative":[139],"tumor":[140,233,248],"volume":[141,234],"(RTV).":[142],"Results:":[143],"A":[144],"inhibition":[150,195],"observed":[152,181],"chemo":[156],"cells":[159,184],"(CIs":[160],"at":[161],"ED90":[162],"0.50":[164],"[5-FU],":[165],"0.71":[166],"[paclitaxel],":[167],"0.76":[168],"[cisplatin],":[169],"0.29":[171],"[gemcitabine]).":[172],"Increased":[173],"decreased":[177],"5-FU":[189],"vs":[190,206],"monotherapy.":[191],"Synergized":[192],"occurred":[196,214],"lines.":[202],"monotherapy,":[207],"significant":[209],"reduction":[210,227],"(P<0.01)":[211],"RTV":[213],"S-1,":[218],"(Table),":[220],"numerically":[225],"greater":[226],"gemcitabine.":[231],"Table.Relative":[232],"xenografts":[238],"therapyTreatment":[246],"(mg/kg/d)Relative":[247],"volumeDay":[249],"0Day":[250],"4Day":[251],"8Day":[252],"11Day":[253],"15Control11.562.373.344.58Futibatinib":[254],"(5)a11.321.952.773.83Futibatinib":[255],"(15)a11.211.822.453.16Paclitaxel":[256],"(60)b10.480.410.410.59Futibatinib":[257],"+":[258,261,263,266,273],"(5":[260],"60)c10.470.270.170.14Futibatinib":[262],"(15":[265],"60)c10.440.220.120.07aDays":[267],"1-14":[268,272],"(oral).bDay":[269],"1":[270],"(intravenous).cDays":[271],"Day":[274],"1.":[275],"Conclusions:":[276],"Futibatinib":[277,312],"showed":[278],"when":[288],"combined":[289],"agents.":[293],"These":[294],"data":[295],"are":[296],"promising":[297],"warrant":[299],"further":[300],"investigation.":[301],"Citation":[302],"Format:":[303],"Hiroshi":[304,310],"Sootome,":[305],"Akihiro":[306],"Miura,":[307],"Toshiharu":[308],"Komori,":[309],"Hirai.":[311],"(TAS-120)":[313],"demonstrates":[316],"across":[320],"models":[328],"[abstract].":[329],"In:":[330],"Proceedings":[331],"Annual":[334],"Meeting":[335],"American":[338],"Association":[339],"for":[340],"Cancer":[341,353],"Research":[342],"2020;":[343],"2020":[344],"Apr":[345],"27-28":[346],"Jun":[348],"22-24.":[349],"Philadelphia":[350],"(PA):":[351],"AACR;":[352],"Res":[354],"2020;80(16":[355],"Suppl):Abstract":[356],"nr":[357],"564.":[358]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2020-09-11T00:00:00"}